This is my second Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM ) article following 02/2025's "Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven". In Genetic Obesity , I rated Rhythm as a "Buy". It has since enjoyed a nice ~28% bump. InWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of invest ...